Invesco
LXEO icon

Invesco’s Lexeo Therapeutics LXEO Stock Holding History

Invesco’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
76,219
+12,701
+20% +$68.7K ﹤0.01% 3384
2026
Q1 		$365K Sell
63,518
-399,511
-86% -$2.83M ﹤0.01% 3269
2025
Q4 		$4.6M Buy
+463,029
New +$4.23M ﹤0.01% 2272

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Invesco's LXEO Position: Q2 2026 in Review

Invesco increased its Lexeo Therapeutics (LXEO) stake by 20% in Q2 2026, buying an estimated $68.7K and bringing the position to 76,219 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #3384.

Invesco first reported a position in LXEO in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.6M in Q4 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Invesco held 76,219 shares of Lexeo Therapeutics worth $355K as of Q2 2026.
  • Invesco bought 12,701 Lexeo Therapeutics shares in Q2 2026, an estimated $68.7K.
  • Lexeo Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3384 holding.
  • Invesco first reported a position in Lexeo Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Invesco's Lexeo Therapeutics position peaked at $4.6M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.